Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.

Background: Rapamycin, an inhibitor of mammalian target of Rapamycin (mTOR), is an immunosuppressive agent that has anti-proliferative effects on some tumors. However, the role of Rapamycin-induced immune suppression on tumor progression has not been examined.

Methods: We developed a transplantation model for generation of mammary tumors in syngeneic recipients that can be used to address the role of the immune system on tumor progression.

High-affinity IgG to a major A. fumigatus allergen, Asp f 2, retards allergic response.

Background: Allergic diseases represent a major health threat to humans. Allergen-specific immunotherapy (SIT) is one of the significant approaches to the treatment of IgE-mediated allergy and its control. The mechanisms involved in SIT-induced responses are complex and still speculative.

The p1 protein of the yeast transposon Ty1 can be used for the construction of bi-functional virus-like particles.

Virus-like particles (VLPs) containing heterologous proteins are often used as vaccines. Two approaches for the construction of bi-functional VLPs using hybrid protein pl-380 of the TY1 transposon of Saccharomyces yeast are described. We have shown that both C- and N-termini of p1-380 can be used for the expression of heterologous peptides.

Immune response modulation by recombinant peptides expressed in virus-like particles.

Aspergillus fumigatus, a ubiquitous fungus, is implicated in the pathogenesis of a number of clinically different allergic diseases in man, including allergic bronchopulmonary aspergillosis. Peptide-based immunotherapy may offer an alternative treatment strategy for the management of allergic disease. The objective of this study was to alter the allergen-specific immune response using dominant T cell epitopes of a major A.

Immunostimulatory activity of Milife, a novel immunomodulator of fungus origin.

Milife is a novel immunomodulator derived from the fungus Fusarium Sambucium. In this study we examined immunomodulatory properties of Milife in 10 months-old BLRB mice. Milife was given to mice orally in a daily dose of 1 mg per mouse, for 2 to 6 days.